Compare KPTI & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | JHS |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 136.5M |
| IPO Year | 2013 | 1994 |
| Metric | KPTI | JHS |
|---|---|---|
| Price | $7.90 | $11.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | ★ 792.1K | 16.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $10.62 |
| 52 Week High | $10.99 | $12.09 |
| Indicator | KPTI | JHS |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 13.58 |
| Support Level | $5.60 | N/A |
| Resistance Level | $7.81 | $11.40 |
| Average True Range (ATR) | 0.76 | 0.11 |
| MACD | -0.24 | -0.05 |
| Stochastic Oscillator | 2.84 | 1.35 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.